Lucida Medical, a spin-off from the University of Cambridge, has developed an artificial intelligence (AI) platform that's set to revolutionise the way we diagnose this prevalent disease.
Dubbed 'Pi', this innovative technology uses AI to identify prostate cancer cases from MRI scans. It's a bit like having a super-smart, tireless radiologist on your team, working round the clock to spot those pesky cancer cells.
Not one to miss out on a good thing, Macmillan Cancer Support has thrown its weight behind the venture, investing a hefty £350,100. This marks the charity's second investment from its £3.5 million Innovation Impact Investment Portfolio, a fund dedicated to supporting start-ups developing pioneering cancer care products.
Why is this a big deal? Well, consider this: Prostate Cancer UK estimates that around 52,000 men are diagnosed with prostate cancer in the UK each year, with 12,000 sadly losing their lives to the disease. Current diagnostic methods include blood tests, MRI scans, and biopsies, but Pi could streamline this process, offering faster, more accurate results.
Lucida Medical's CEO, Dr Antony Rix, believes that Pi's potential to avoid unnecessary biopsies could be transformative for both the NHS and patients. And he's not alone in his enthusiasm. Tanya Humphreys, Director of Innovation at Macmillan, shares his excitement, stating that Pi "has the potential to transform the diagnosis of prostate cancer".
So, what's next for Lucida Medical? With Macmillan's backing and the support of its Innovation Community, the company will continue to develop Pi, aiming to make a real difference in the lives of those affected by prostate cancer. Stay tuned, folks, the future of cancer detection is looking brighter by the day!
Made with TRUST_AI - see the Charter: https://www.modelprop.co.uk/trust-ai
Comentários